Related Experiment Video
Updated: Mar 27, 2026

Author Spotlight: Development and Evaluation of a Compound Acne Rodent Model Using C. acnes and Oleic Acid
Published on: November 1, 2024
Evolution of Acne Assessments and Impact on Acne Medications: An Evolving, Imperfect Paradigm
Background:
Outcomes for success in acne interventional trials include statistically significant differences from baseline between treatment arms in lesion counts (comedonal, inflammatory and/or total) and in thresholds of categorical improvement in investigator global assessments (IGA).
Objectives:
We evaluated differences in outcome measures and definition of success in acne trials; and their impact on FDA approval and indications for acne medications.
Methods:
Review of acne clinical trial literature, prescribing information and regulatory guidelines for currently approved acne medications in the United States.
Results:
Numerous IGA scales exist with variations in specific categorical definitions. There are also differences in definitions of global success. Outcome success may not be accurately translated into corresponding terminology for indications.
Conclusions:
Variability in IGA scales and definitions of success confound comparison of trial results for acne treatments. Harmonization and standardization of these factors will facilitate meta-analytics and treatment selection in patient care. Outcome measure success has not consistently been incorporated into acne medication indications.
Insights
Standardizing investigator global assessments (IGA) and success definitions in acne clinical trials is crucial. This harmonization will improve treatment comparisons and patient care by clarifying outcomes for acne medications.
Area of Science:
- Dermatology
- Clinical Trials
- Regulatory Science
Background:
- Acne interventional trial success is typically measured by changes in lesion counts and investigator global assessments (IGA).
- Existing outcome measures include statistically significant differences between treatment arms and categorical improvements defined by IGA thresholds.
Purpose of the Study:
- To evaluate variations in outcome measures and success definitions within acne clinical trials.
- To assess the impact of these variations on Food and Drug Administration (FDA) approval and medication indications.
Main Methods:
- A comprehensive review of published acne clinical trial literature was conducted.
- Prescribing information for currently approved acne medications in the United States was analyzed.
- Relevant regulatory guidelines were examined.
Main Results:
- Multiple investigator global assessment (IGA) scales exist, differing in their specific categorical definitions.
- Definitions of overall success in trials exhibit considerable variation.
- Outcome success metrics are not consistently translated into precise terminology for medication indications.
Conclusions:
- Discrepancies in IGA scales and success definitions hinder the comparison of acne treatment trial results.
- Standardization of these elements is essential for facilitating meta-analyses and informed patient treatment selection.
- Outcome measure success has not been uniformly integrated into acne medication indications.
Related Concept Videos
Acne Infection
Mechanism of Antibiotic Resistance in MRSA
Accessory Structures of the Skin: Sebaceous Glands
These glands that produce the oils on the skin and hair are holocrine glands. The mature...
Evolution of New Traits in Microbes
Clinical Significance of Antibiotic Resistance
The Skin Microbiota

